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Protein degradation by the ubiquitin (Ub) system controls the con-
centrations of many regulatory proteins. The degradation signals
(degrons) of these proteins are recognized by the system’s Ub ligases
(complexes of E2 and E3 enzymes). Two substrate-binding sites of
UBR1, the E3 of the N-end rule pathway in the yeast Saccharomyces
cerevisiae, recognize basic (type 1) and bulky hydrophobic (type 2)
N-terminal residues of proteins or short peptides. A third substrate-
binding site of UBR1 targets CUP9, a transcriptional repressor of the
peptide transporter PTR2, through an internal (non-N-terminal) de-
gron of CUP9. Previous work demonstrated that dipeptides with
destabilizing N-terminal residues allosterically activate UBR1, leading
to accelerated in vivo degradation of CUP9 and the induction of PTR2
expression. Through this positive feedback, S. cerevisiae can sense the
presence of extracellular peptides and react by accelerating their
uptake. Here, we show that dipeptides with destabilizing N-terminal
residues cause dissociation of the C-terminal autoinhibitory domain
of UBR1 from its N-terminal region that contains all three substrate-
binding sites. This dissociation, which allows the interaction between
UBR1 and CUP9, is strongly increased only if both type 1- and type
2-binding sites of UBR1 are occupied by dipeptides. An aspect of
autoinhibition characteristic of yeast UBR1 also was observed with
mammalian (mouse) UBR1. The discovery of autoinhibition in Ub
ligases of the UBR family indicates that this regulatory mechanism
may also control the activity of other Ub ligases.
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Ubiquitin (Ub) is conjugated to other proteins through theaction of three enzymes, E1, E2, and E3 (1–4). A ubiquitylated
protein substrate that is targeted for degradation bears a covalently
linked multi-Ub chain, which mediates the binding of substrate by
the 26S proteasome, an ATP-dependent protease (5). The selec-
tivity of ubiquitylation is determined by E3, which recognizes a
substrate’s degradation signal (degron; refs. 3 and 6–9). The term
‘‘Ub ligase’’ denotes either an E2-E3 complex or its E3 component.
One Ub-dependent proteolytic pathway, called the N-end rule
pathway, targets proteins bearing destabilizing N-terminal residues
(10–17). The corresponding degron, called the N-degron, consists
of a substrate’s destabilizing N-terminal residue and an internal
lysine residue (18, 19). In Saccharomyces cerevisiae, the 225-kDa,
RING domain-containing Ub ligase UBR1 recognizes primary
destabilizing N-terminal residues of two types: basic (type 1: Arg,
Lys, and His) and bulky hydrophobic (type 2: Phe, Leu, Tyr, Trp,
and Ile; ref. 11). Several other N-terminal residues function as
tertiary (Asn, Gln) and secondary (Asp, Glu) destabilizing residues,
in that they are recognized by UBR1 after their enzymatic conju-
gation to Arg, a primary destabilizing residue (17, 20). In the case
of N-terminal Asn and Gln (and also Cys in metazoans), this
conjugation is preceded by other enzymatic modifications (17, 21,
22). Dipeptides bearing either basic (type 1) or bulky hydrophobic
(type 2) N-terminal residues have been shown to inhibit degrada-
tion of N-end rule substrates through competition with substrates
for binding to the type 1 or type 2 sites of UBR1 (13, 14, 20, 23).
The emerging physiological roles of the N-end rule pathway have
been reviewed (11, 13, 15–17, 22, 24, 25). One function of the
S. cerevisiae N-end rule pathway is the control of peptide import
through regulated degradation of the 35-kDa homeodomain pro-
tein CUP9, a transcriptional repressor of the di- and tripeptide
transporter PTR2 (13, 24, 25). CUP9 contains an internal (C
terminus-proximal) degron which is recognized by a third substrate-
binding site of UBR1. Previous work (13) has shown that the
UBR1-dependent degradation of CUP9 is allosterically activated by
dipeptides with destabilizing N-terminal residues. In the resulting
positive feedback, imported dipeptides bind to UBR1 and accel-
erate the UBR1-dependent degradation of CUP9, thereby dere-
pressing the expression of PTR2 and increasing the cell’s capacity
to import peptides (13).
Here, we address the mechanism through which dipeptides that
bind to UBR1 accelerate the degradation of CUP9. We discovered
that this mechanism involves autoinhibition of UBR1.
Materials and Methods
Extracts of S. cerevisiae Expressing UBR1 or Its Derivatives. N-
terminally flag-tagged (26), full-length S. cerevisiae UBR1 (fUBR1)
and its truncated derivatives were expressed in S. cerevisiae from the
PADH1 promoter in a high-copy plasmid, followed by preparation of
an extract containing fUBR1 or its derivatives.
GST-Pulldown Assay. DNA fragments encoding either WT CUP9,
its mutant derivatives, RAD6, the 273-residue C-terminal fragment
of S. cerevisiae UBR1 (UBR11678–1950), or the 259-residue C-
terminal fragment of mouse UBR1 (mUBR11499–1757) were sub-
cloned into pGEX-2TK (Amersham Pharmacia), downstream
of and in frame with the ORF of GST. The final constructs (except
the one containing RAD6) also bore the C-terminal His-6 tag (26).
The resulting plasmids were expressed in Escherichia coli, and the
corresponding proteins were purified by affinity chromatography
with Ni-NTA resin (Qiagen). GST-pulldown assays with S. cerevi-
siae extracts containing fUBR1 or its derivatives were carried out as
described (27).
Pulldown Assay with Peptide Beads. 12-mer peptides, XIFSTDTG-
PGGC (in single-letter abbreviations for amino acids), with the
N-terminal residue X being Arg, Phe, Gly, Ser, Thr, Ala, or Asp,
were crosslinked via its C-terminal Cys residue to UltraLink
Iodoacetyl beads (Pierce), followed by a pulldown assay carried out
similarly to GST-pulldowns with S. cerevisiae extracts containing the
overexpressed, full-length S. cerevisiae fUBR1.
Pulse–Chase Assay. Ub fusion proteins of the UPR (Ubprotein
reference) technique (19, 28) were expressed in S. cerevisiae from
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low-copy plasmids and the PMET25 promoter. Upon cotranslational
cleavage by deubiquitylating enzymes (DUBs), these fDHFR-Ub-
CUP9f fusions yielded the long-lived reference protein flag-
dihydrofolate reductase-Ub (fDHFR-Ub) and either the C-
terminally f lag-tagged WT CUP9 (CUP9f) or its mutant
derivatives. Pulse-chases were carried out essentially as described
(13, 15, 19). See Supporting Methods, which is published as sup-
porting information on the PNAS web site, www.pnas.org.
Results and Discussion
Pairs of Type 1 and Type 2 Dipeptides Greatly Increase the Apparent
Affinity of UBR1 for CUP9. UBR1-CUP9 interactions were examined
by using GST-pulldown assays. Equal amounts of extract from S.
cerevisiae overexpressing flag-tagged UBR1 (fUBR1) were incu-
bated in either the absence or presence of various dipeptides (at 1
mM) with glutathione-Sepharose beads preloaded with GST-
CUP9. The bound proteins were eluted, fractionated by SDS
PAGE, and the bound fUBR1 was assessed by immunoblotting. The
cognate Ub-conjugating (E2) enzyme RAD6 (GST-RAD6), a
known UBR1 ligand (12), bound to fUBR1, whereas GST alone did
not, in either the presence or absence of dipeptides (Fig. 1A, lanes
2 and 10; Fig. 1B, lane 10; Fig. 1C, lane 10). In the absence of added
dipeptides or in the presence of dipeptides with stabilizing N-
terminal residues, such as Ala-Arg or Ala-Leu, fUBR1 exhibited a
detectable but weak binding to GST-CUP9 (Fig. 1A, lanes 3, 5, and
7). This binding was slightly but reproducibly increased in the
presence of Arg-Ala, a type 1 dipeptide, but not in the presence of
Leu-Ala, a type 2 dipeptide (Fig. 1A, lanes 4 and 6 vs. lanes 3, 5, and
7). Remarkably, the binding of fUBR1 to GST-CUP9 was greatly
increased in the presence of both type 1 and type 2 dipeptides,
Arg-Ala and Leu-Ala (Fig. 1A, lane 8 vs. lanes 3, 4, and 6). Other
combinations of type 1 dipeptides (Lys-Ala and His-Ala) and type
2 dipeptides (Phe-Ala and Trp-Ala) yielded similar results. Specif-
ically, a strong enhancement of the fUBR1-CUP9 interaction was
observed only if both a type 1 and a type 2 dipeptide were present
in the binding assay (Fig. 1 A–C). The synergistic effect of a pair of
type 1 and type 2 dipeptides became detectable at 10 M Arg-Ala
plus 10M Leu-Ala, was strongly increased at 0.1 mM, and reached
near-saturation at 1 mM Arg-Ala plus 1 mM Leu-Ala (Fig. 1D and
data not shown). In contrast to type 1 and type 2 dipeptides, the
corresponding free amino acids did not increase the binding of
UBR1 to CUP9 in several tested combinations (data not shown).
The above effect (Fig. 1) makes UBR1, operationally, a sensor
for the simultaneous presence of both type 1 and type 2 dipeptides.
To determine whether this property of UBR1 could be detected at
the level of dipeptide uptake in vivo, we used S. cerevisiae auxotro-
phic for Leu. Ala-Leu, bearing a stabilizing N-terminal residue,
could not rescue the strain’s growth if present at 230 M in the
growth medium (Fig. 2 C and D). However, the growth was rescued
if the Leu-lacking type 1 and type 2 dipeptides Arg-Ala and Phe-Ala
were present together at 0.6 M each, in addition to 230 M
Ala-Leu (Fig. 2 C and D). Under the same conditions, Arg-Ala
alone (type 1 dipeptide) was significantly less effective, whereas
Phe-Ala alone (type 2 dipeptide) could not rescue cell growth (Fig.
2 C and D). Because food sources of S. cerevisiae in the wild are
likely to contain diverse mixtures of short peptides, the sensitivity
of UBR1–CUP9 interaction to the simultaneous presence of a type
1 and a type 2 dipeptide is likely to be physiologically relevant. At
higher concentrations in the medium (2 M), single dipeptides
with destabilizing N-terminal residues were observed to stimulate
the import of a nutritionally essential dipeptide bearing a stabilizing
N-terminal residue (13). This may result, for example, from sub-
threshold in vivo levels of diverse dipeptides present in cells at all
times andor from a highly cooperative dose-response aspect of
peptide import, given the circuit’s positive feedback (13).
Specificity of UBR1 Interactions with CUP9 and Ligands Bearing
Destabilizing N-Terminal Residues. GST-pulldowns also were per-
formed with metabolically stabilized CUP9 mutants (Fig. 2B)
isolated through a genetic screen (F.N.-G., G. Turner, and A.V.,
unpublished data). All of the substitutions were located within the
last 33 residues of the 306-residue CUP9, thereby defining an
essential part of the CUP9 degron (Fig. 2B). An inverse correlation
was observed between the in vivo half-lives of CUP9 mutants and
the extent of their binding to UBR1 in GST-pulldowns (Fig. 7,
which is published as supporting information on the PNAS
web site).
By using crosslinking and coimmunoprecipitation assays, previ-
ous work has shown that proteins bearing destabilizing N-terminal
residues specifically bind to S. cerevisiae UBR1 (6). We extended
this evidence through pulldown assays with synthetic 12-mer pep-
tides of the sequence XIFSTDTGPGGC (in single-letter abbrevi-
ations for amino acids) (XArg, Phe, Ser, Thr, Gly, Ala, or Asp).
These peptides were crosslinked to microbeads through their
C-terminal Cys residue. fUBR1 bound to the 12-mer peptides
Fig. 1. Type 1 and type 2 dipeptides, if present together, greatly increase the
binding of UBR1 to CUP9. Equal amounts of an extract from S. cerevisiae over-
expressing the N-terminally flag-tagged UBR1 (fUBR1) were incubated with
glutathione-Sepharose beads preloaded with either GST alone, GST-CUP9, or
with GST-RAD6, in either the presence or absence of dipeptides. The bound
proteins were eluted, fractionated by SDSPAGE, and immunoblotted with anti-
flag antibody. Unless otherwise stated, each dipeptide was present at 1 mM. *,
Fragment of fUBR1. The ‘‘5% input’’ lanes refer to a directly loaded sample of the
yeast extract that corresponded to 5% of the extract’s amount used in the
GST-pulldown assays.
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bearing N-terminal Arg or Phe (type 1 and type 2 primary desta-
bilizing residues; Fig. 3A, lanes 2 and 6; Fig. 3B, lanes 4 and 5), but
did not bind to the otherwise identical peptides bearing either
N-terminal Gly (a stabilizing residue) or Asp (a secondary desta-
bilizing residue; Fig. 3B, lanes 3 and 6). The same results were
obtained with 12-mer peptides bearing other stabilizing N-terminal
residues such as Ser, Thr, or Ala.
At 10 mM, the added dipeptides Ala-Arg and Ala-Phe, bearing
a stabilizing N-terminal residue (Ala), did not significantly inhibit
the binding of UBR1 to either Arg- or Phe-bearing 12-mer peptides
(Fig. 3A, lanes 5 and 9). In contrast, the Arg-Ala dipeptide
abolished the binding of UBR1 to the Arg-bearing 12-mer peptide,
and Phe-Ala had the same effect on the binding of UBR1 to the
Phe-bearing 12-mer peptide (Fig. 3A, lanes 3 and 8). This inhibition
was selective, in that Phe-Ala did not abolish the binding of UBR1
to Arg-bearing 12-mer peptide, and Arg-Ala did not abolish the
binding of UBR1 to Phe-bearing 12-mer peptide (Fig. 3A, lanes 4
and 7). Similar results were obtained when mouse UBR1 (E3) was
used as a ligand in otherwise identical assays, instead of S. cerevisiae
UBR1 (data not shown). No binding of UBR1 to the Gly-, Ser-,
Thr-, Ala-, or Asp-bearing 12-mer peptides could be detected even
after strong overexposure of autoradiograms. By a conservative
estimate, the affinity of UBR1 for primary destabilizing N-terminal
residues such as Arg and Phe was at least 100-fold higher than the
affinity of UBR1 for stabilizing (or secondary destabilizing) N-
terminal residues. The actual difference is likely to be significantly
larger than 100-fold, because recent measurements using the flu-
orescence polarization technique and fluorescently labeled 12-mer
peptides could not detect the binding of UBR1 to a Gly-bearing
peptide under conditions in which UBR1 bound an otherwise
identical peptide bearing N-terminal Phe with a Kd of 1 M
(Z.X. and A.V., unpublished data).
Recently, Baboshina et al. (29) suggested that the mammalian
N-end rule pathway distinguishes between stabilizing and destabi-
lizing N-terminal residues not through differences in the thermo-
dynamic affinities of UBR1 (E3) for these residues, but largely
through differences in the catalytic activity of UBR1 in response to
its (comparably avid) binding to either stabilizing or destabilizing
N-terminal residues. This conclusion, based on the authors’ inter-
pretation of their enzymological evidence (29), is directly in conflict
with both the earlier UBR1-binding data (6) and the results above.
The technically straightforward, catalysis-free binding assays with
yeast and mouse UBR1 (Fig. 3, and similar data with mouse UBR1
not shown) confirmed and extended the earlier evidence (6) that
the specificity of N-degron’s recognition stems, in the main, from
large differences in the affinity of UBR1 for destabilizing vs.
Fig. 3. Specific binding of the S. cerevisiae ubiquitin ligase UBR1 to peptides
bearing destabilizing N-terminal residues. Equal amounts of an extract from S.
cerevisiae overexpressing the N-terminally flag-tagged UBR1 (fUBR1) were incu-
bated with microbeads crosslinked to the C terminus of a 12-mer peptide XIFST-
DTGPGGC (X Arg, Phe, Ser, Thr, Gly, Ala, or Asp), followed by washes, elution
of the bound proteins, SDSPAGE, and immunoblotting with anti-flag antibody
(see supporting information). (A) Lane 1: 2% of the initial extract’s sample. Lanes
2–5: the binding of fUBR1 to beads-linked RIFSTDTGPGGC, bearing N-terminal
Arg, in the absence of presence of specific dipeptides. Lanes 6–9: analogous
assays with FIFSTDTGPGGC, bearing N-terminal Phe. (B) Lane 1: 5% of the initial
extract’s sample. Lanes 2–6: fUBR1 binding assay, in the absence of added dipep-
tides, with either mock-crosslinked beads (0) or the beads with 12-mer peptides
bearing N-terminal Gly, Arg, Phe, and Asp, respectively.
Fig. 2. S. cerevisiae UBR1, CUP9, and plating efficiency assays. (A) A diagram of
S. cerevisiae UBR1, indicating the regions conserved in the fungal and metazoan
UBR proteins (16, 30). His and Cys are two of the conserved residues in the UBHC
region (UBRHisCys; residues 123–193) that encompass Gly-173 and Asp-176,
which are essential for the integrity of the type 1 substrate-binding site of UBR1
(A. Webster, M. Ghislain, and A.V., unpublished data). See the main text for
descriptions of the BRR, RING-H2, and UBLC regions. Also shown are the deriva-
tivesofUBR1used in theGST-CUP9-bindingassaysandafragmentcontainingthe
UBLC domain (used as GST-UBR11678–1950) in the binding assay with UBR11–1140
and UBR11678–1950. UBR1 and its fragments bore N-terminal flag, except for
UBR11–1140, which contained C-terminal flag. (B) A diagram of the 306-residue
CUP9 highlighting its homeodomain, the site of the toxicity-reducing Asn-
2153Ser mutation (13) and the C-terminal region, whose sequence is shown
below together with the alterations that decreased the UBR1-dependent deg-
radation of the corresponding CUP9 mutants in yeast (see supporting informa-
tion). (C) Plating efficiency assays, carried out in minimal medium with S. cerevi-
siae SC295 (Leu) in the presence of 230 M Ala-Leu and the indicated pairs of
nonnutritious dipeptides at 0.6 M each. (D) Representative images of plates
from the assays in C.
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stabilizing N-terminal residues. Specific reasons for the incorrect-
ness of the conclusion by Baboshina et al. (29) are unclear, save for
the notion that inferences about the relative thermodynamic affin-
ities should properly be based on assays that compare the affinities
themselves, in a catalysis-free setting.
N-Terminal Half of the 225-kDa UBR1 Binds CUP9 in Either the Presence
or Absence of Dipeptides. The type 1- and type 2-binding sites of
UBR1 have been mapped, using a genetic screen, to an 600-
residue N-terminal region of the 1,950-residue UBR1 (A. Webster,
M. Ghislain, and A.V., unpublished data). To locate the region of
UBR1 that recognizes CUP9 (Fig. 2B), we examined the binding of
GST-CUP9 to fUBR11–1175 and fUBR11–717, two N-terminal frag-
ments of fUBR1 (Fig. 2A). (The superscript numbers refer to
residue positions in the untagged WT UBR1.) These assays, carried
out in the presence of 1 mM Arg-Ala plus 1 mM Leu-Ala, showed
that fUBR11–1175 bound to GST-CUP9, whereas fUBR11–717 did not
(Fig. 4B), indicating that sequences between residues 717 and 1175
were required for the UBR1 binding to CUP9. Both fUBR11–1175
(which bound to CUP9) and fUBR11–717 (which did not bind to
CUP9) retained the capacity to bind either dipeptides or test
proteins bearing destabilizing N-terminal residues (data not
shown).
Remarkably, whereas strong binding of fUBR1 to GST-CUP9
required the presence of a pair of type 1 and type 2 dipeptides (Fig.
1), no such dependence was observed with the fUBR11–1175 frag-
ment: it exhibited strong binding to GST-CUP9 under both con-
ditions (Fig. 4A). Additional assays, using mutant CUP9 moieties,
confirmed the specificity of the observed interaction, in that
fUBR11–1175 and full-length fUBR1 exhibited similar patterns of
affinity for the CUP9 mutants (Fig. 2 B and D and Fig. 7).
fUBR11–1175 lacked the RING-H2 domain of UBR1 but contained
its basic residues-rich (BRR) region (Fig. 2A). Together, these
adjacent regions mediate the interaction between UBR1 and the E2
enzyme RAD6 (12). UBR11–1140f, which lacked the entire RAD6-
binding site (Fig. 2A), also bound to GST-CUP9 constitutively (Fig.
4D). Thus, the CUP9-binding site and the RAD6-binding site can
be separated in UBR1 fragments.
A Conserved C-Terminal Region of Yeast and Mouse UBR1 Binds to the
N-Terminal Half of UBR1. fUBR11–1367 and UBR11–1140f, which,
respectively, contained and lacked the RAD6-binding site (Fig.
2A), bound to GST-CUP9 with similar affinities (Fig. 5B, lanes 4–6
vs. lanes 1–3). In contrast, both of the longer fragments, fUBR11–
1540 and fUBR11–1700, exhibited weak binding to GST-CUP9 in
either the presence or absence of Arg-Ala plus Leu-Ala (Fig. 5A,
lanes 7–9, and Fig. 5B, lanes 7–9). The still longer fUBR11–1818
fragment, which encompassed the 108-residue, C terminus-
proximal region termed UBLC (UBRLeuCys; Fig. 2A; refs. 16
and 30), bound to GST-CUP9 strongly in the presence of Arg-Ala
plus Leu-Ala; the omission of dipeptides decreased the binding, but
to a lesser extent than with the full-length fUBR1 (Fig. 5A, lanes 4–6
vs. lanes 1–3). The UBLC domain of UBR1 (Fig. 2A; ref. 30)
contains two conserved cysteines, Cys-1703 and Cys-1706.
fUBR1C1703,1706S(A), two functionally inactive variants of the full-
length UBR1 in which both Cys residues were converted to either
Ser or Ala, exhibited a pattern of CUP9 binding similar to that of
fUBR11–1700, which lacks the entire UBLC domain (Fig. 5C vs. Fig.
5A, lanes 7–9). Thus, Cys-1703 and Cys-1706 are essential for the
functions of the UBLC domain.
The type 1- and type 2-binding sites, as well as the third
(CUP9-binding) site of UBR1, are located within the first 1,140
residues of the 1,950-residue UBR1 and precede the RAD6-
binding site, which consists of the adjacent BRR and RING-H2
domains (12). As shown in Fig. 4 A, C, and D, the 600-residue
C-terminal region of UBR1, downstream from the RING-H2
domain (Fig. 2A), is required for the suppression of CUP9 binding
to UBR1 in the absence of dipeptides but is not required for the
high-affinity interaction between UBR1 and CUP9. Thus, the
binding of CUP9 by WT UBR1 is autoinhibited by its C-terminal
region, which folds back and interacts, in part, through the UBLC
domain (see below) with a region that encompasses (or is adjacent
to) the CUP9-binding site of UBR1. In this ‘‘closed’’ conformation,
steric hindrance by the C-terminal region of UBR1 precludes the
binding of UBR1 to CUP9 (Fig. 6). A pair of type 1 and type 2
dipeptides synergistically relieves the autoinhibition by inducing an
opening of the closed UBR1 conformation, thus abolishing the
occlusion of the CUP9-binding site.
In the absence of type 1 and type 2 dipeptides, the probability of
closed3open transition in UBR1 is small. As a result, there are few
UBR1 molecules in the open conformation that are capable of
binding to CUP9, thus accounting for the observed weak binding of
UBR1 to CUP9 in the absence of dipeptides (Fig. 1). A pair of type
Fig. 4. Dipeptide-independent, high-affinity binding of CUP9 by N-terminal
fragments of UBR1. (A) GST-pulldowns with fUBR11–1175 and GST-CUP9 in the
presence of different dipeptides (at 1 mM each). (B) As in A, in the presence of 1
mM Arg-Ala and 1 mM Leu-Ala, with either GST alone or GST-CUP9 and either
full-length fUBR1, fUBR11–1175, or fUBR11–717. (C) GST-pulldowns with either full-
length fUBR1 or fUBR11–1175 in the presence of either 1 mM Arg-Ala and 1 mM
Leu-Ala () or 1 mM Ala-Arg and 1 mM Ala-Leu (). Two input amounts of
fUBR11–1175, differing by 6-fold, were used (lanes 2 and 3). The corresponding
fUBR11–1175 assays are in lanes 7 and 8 vs. 9 and 10, respectively. (D) Comparisons,
in the presence of either 1 mM Arg-Ala and 1 mM Leu-Ala () or 1 mM Ala-Arg
and1mMAla-Leu ()of thebindingof fUBR1andUBR11–1140f toeitherGST-CUP9
or GST-RAD6. *, Crossreacting proteins.
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1 and type 2 dipeptides, upon their binding to the type 1 and type
2 sites of UBR1, increases the probability of closed3open transi-
tion, causing a larger fraction of UBR1 molecules to acquire the
binding-competent conformation and yielding the observed strong
binding to CUP9 (Fig. 6). According to this (parsimonious) model,
the weak binding of UBR1 to CUP9 in the absence of a pair of type
1 and type 2 dipeptides (Fig. 1) reflects not a weak binding of CUP9
by most UBR1 molecules, but rather a low but nonzero probability
of the closed3open transition in UBR1 under these conditions. In
other words, the apparently weak binding of UBR1 for CUP9 in the
absence of dipeptides (Fig. 1) is a manifestation of the strong
binding of CUP9 by a minority of open-conformation UBR1
molecules in the largely closed-conformation UBR1 ensemble
(Fig. 6).
We carried out yet another test of this model by asking whether
UBR11678–1950, the 273-residue C-terminal fragment of UBR1 that
contained the UBLC domain, could bind, in trans, to fUBR11–1140,
the N-terminal fragment of UBR1 that contained all three of its
substrate-binding sites but lacked the RAD6-binding site (Fig. 2A).
fUBR11–1140 indeed bound to the UBLC-containing GST-
UBR11678–1950 fragment (Fig. 5D). Remarkably, this interaction
was strongly inhibited by a type 2 dipeptide (Leu-Ala) but neither
by a type 1 dipeptide (Arg-Ala) nor by dipeptides with stabilizing
N-terminal residues (Fig. 5D).
Mouse UBR1 (E3), a homolog of S. cerevisiae UBR1, is a
1,757-residue Ub ligase of the N-end rule pathway, one of at least
three E3s (UBR1, UBR2, and an unidentified E3) that mediate this
pathway in the mouse (16, 30). We asked whether GST-
mUBR11499–1757, the UBLC-containing C-terminal fragment of
mouse UBR1, binds to mfUBR11–1031, the N-terminal half of mouse
UBR1, similarly to the key interaction identified with yeast UBR1
(Fig. 5D). The above fragments of mouse UBR1 were indeed found
to interact, and moreover, dipeptides with destabilizing N-terminal
residues, in contrast to dipeptides with stabilizing N-terminal
residues, inhibited the interaction of two fragments (Fig. 5E).
Regulated Autoinhibition of a Ub Ligase. The model of autoinhibition
proposed in Fig. 6 is consistent with the data of this work and
explains several earlier observations as well. This model posits that
the binding of Arg-Ala to the (always accessible) type 1 site of
UBR1 induces a conformational change that increases the acces-
sibility (andor affinity) of the type 2-binding site to Leu-Ala. It is
the latter binding event that induces the closed3open transition in
UBR1 and the unmasking of its CUP9-binding site. In addition to
accounting for the fact that both type 1 and type 2 dipeptides must
be present together for a strong increase in the binding of full-length
UBR1 to CUP9 (Fig. 1), this sequential-binding mechanism is also
consistent with the finding that a type 2 dipeptide alone, but not a
type 1 dipeptide alone, is sufficient for abolishing the binding of the
UBLC-containing C-terminal fragment UBR11678–1950 to the N-
terminal fragment UBR11–1140 (Fig. 5D). Specifically, whereas the
binding of a type 1 dipeptide increases the accessibility of the type
2-binding site in the full-length UBR1, the type 2 site is likely to be
always accessible in the complex of UBR11–1140 with UBR11678–1950,
because UBR11678–1950 contains the UBLC domain but not the
entire C-terminal region of UBR1 (Fig. 6). Interestingly, the
Fig. 5. The C-terminal UBLC domain of UBR1 binds to the N-terminal region of
UBR1. (A) GST-pulldowns with GST-CUP9 and either full-length fUBR1, fUBR11–
1818, or fUBR11–1700 in the presence of either 1 mM Arg-Ala and 1 mM Leu-Ala ()
or 1 mM Ala-Arg and 1 mM Ala-Leu (). (B) As in A, but with UBR11–1140f,
fUBR11–1367, and fUBR11–1540. (C) As in A, but with full-length WT fUBR1 and its
full-length derivatives fUBR1C1703,1706A and fUBR1C1703,1706S. (D) GST-pulldown for
the interaction between UBR11–1140f and GST-UBR11678–1950 (see Fig. 2A and the
main text) in the presence of different dipeptides. Lanes 9 and 10: results of
analogous assays with UBR11–1140f and either GST-RAD6 or GST-CUP9. *, Cross-
reacting protein. (E) Lanes 1–8: as in D, but with S. cerevisiae extract containing
mfUBR11–1031, the N-terminally flag-tagged N-terminal fragment of the mouse
UBR1 (E3) Ub ligase, and with GST-mUBR11499–1757, a C-terminal fragment of
mouse UBR1, linked to glutathione-Sepharose beads. Lane 9: GST-pulldown with
of mfUBR11–1031 and Leu-SCC1-GST, a GST fusion to a fragment of S. cerevisiae
SCC1 (15) bearing N-terminal Leu, a type 2-destabilizing residue. Lane 10:
mfUBR11–1031 and GST-mHR6A, one of the cognate mouse E2 enzymes that bind
tofull-lengthmUBR1(16). LackingtheRING-H2domain,mousemfUBR11–1031 and
yeastUBR11–1140f didnot interactwiththecognateE2enzymes,mouseHR6A,and
yeast RAD6 (D and E), which bind to full-length mouse and yeast UBR1s, respec-
tively (12, 16). Mouse mfUBR11–1031 retained the substrate-binding sites, as could
be demonstrated through its binding to a fragment of the S. cerevisiae SCC1
protein (15) bearing N-terminal Leu, a primary destabilizing residue (lane 9), but
not to an otherwise identical SCC1 fragment bearing a stabilizing N-terminal
residue (data not shown).
Fig. 6. Regulated autoinhibition of the ubiquitin ligase UBR1. See the main
text for description of the model. The CUP9-binding site of UBR1 is denoted by
‘‘i’’ (a site binding to a substrate’s internal degron). The RAD6-binding site is
depicted in this orientation solely to indicate its constitutive availability, in
contrast to the CUP9-binding site.
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sequential-binding mechanism (Fig. 6) also accounts for two earlier
findings: that type 1 dipeptides accelerate the degradation of type
2 protein substrates by the N-end rule pathway, whereas type 2
dipeptides do not accelerate the degradation of type 1 substrates
(16, 20, 23).
Neither the full-length fUBR1C1703,1706S(A) mutants nor the
fUBR11–1700 fragment of WT UBR1 that lacked the UBLC domain
could rescue the N-end rule pathway in ubr1 S. cerevisiae, even
upon overexpression (data not shown). Thus, the C terminus-
proximal UBLC domain (Fig. 2A) performs yet another, currently
unknown in vivo function, in addition to making possible the closed
conformation of UBR1 (Fig. 6). One possibility is that the UBLC
domain might be the site of a UbUBR1 thioester. Although
UBR1 and other E3s of the RING-domain family are presumed not
to form UbE3 thioesters, in contrast to the HECT-domain family
of E3s (2, 3), the possibility of a functionally relevant Ub thioester
in a RING-containing E3 remains to be precluded definitively, at
least with UBR1.
Autoinhibition is an essential feature of many regulatory pro-
teins, including protein kinases and phosphatases (31, 32), nitric
oxide synthases (33), transcription factors (34), and regulators of
actin polymerization (35–37). The synergistic activation of the
UBR1–CUP9 interaction through the binding of both type 1 and
type 2 dipeptides to UBR1 (Fig. 6) is an example of positive signal
integration by a regulatory protein, a property that approximates a
logical AND gate. Among the previously described proteins whose
input–output patterns approximate an AND gate are N-WASP, a
regulator of actin polymerization, and the cell cycle-regulating
CDK kinases (reviewed in ref. 38).
Autoinhibition has not been reported for Ub ligases. UBR1,
UBR2, and UBR3, the mouse homologs of S. cerevisiae UBR1,
contain the conserved UBHC, RING-H2, and UBLC domains
(Fig. 2A, and refs. 16 and 30). In addition, mouse UBR1 and UBR2
contain binding sites for the type 1- and type 2-destabilizing
N-terminal residues. Moreover, the functional properties of these
sites in mouse UBR1 and UBR2, such as the ability of type 1
dipeptides to stimulate the degradation of type 2 N-end rule
substrates, are also similar to those of yeast UBR1 (16, 20, 23).
Finally, an aspect of autoinhibition characteristic of yeast UBR1
was also observed with mouse UBR1 (Fig. 5E). Thus, it is highly
likely that metazoan E3s of the UBR family also are controlled
through autoinhibition, similarly to yeast UBR1. The S. cerevisiae
UBR2 E3 and mouse UBR3 E3, whose functions remain unknown,
are not a part of the N-end rule pathways in the respective
organisms (H. Rao, T.T., Y. T. Kwon, and A.V., unpublished data).
Thus, the (postulated) autoinhibition of yeast UBR2 and mouse
UBR3 may be regulated by naturally occurring small compounds
distinct from dipeptides. Identifying these compounds will provide
a clue to still unknown physiological roles of the UBR-family Ub
ligases that function outside the N-end rule pathway.
The discovery of autoinhibition in the Ub ligases of the UBR
family indicates that this regulatory mechanism may control the
activity of other Ub ligases as well. Our findings also suggest that
natural compounds (either small molecules or proteins) may reg-
ulate the activity of diverse Ub-dependent pathways through the
suppression or induction of autoinhibition in Ub ligases.
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